Overview

Gastrectomy Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric Cancer With a Single Non-curable Factor

Status:
Enrolling by invitation

Trial end date:
2022-01-01

Target enrollment:
0

Participant gender:
All

Summary

Investigators assessed the effectiveness of conversional gastrectomy compared with chemotherapy alone following docetaxel, oxalipaltin and S1 therapy for advanced gastric cancer with a single non-curable factor.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Docetaxel
Oxaliplatin
Tegafur

Criteria

Inclusion Criteria:

- Clinical diagnosis of gastric cancer with a single non-curable factor

- A single non-curable factor was defined as hepatic metastasis (H1; two to four lesions
of maximum diameter ≤5 cm and minimum diameter ≥1 cm); peritoneal metastasis (P1) in
the diaphragm or peritoneum caudal to the transverse colon without massive ascites or
intestinal obstruction; positive cytology (CY1) when the cancer cells were found in
the peritoneal washing; para-aortic lymph node (PAN) metastasis above the coeliac axis
or below the inferior mesenteric artery (lymph node 16a1/b2 of maximum diameter ≥1
cm), or both; or ovary implant metastasis for one site or two.

Exclusion Criteria:

- Patients who can have radical resection.

- Patietns who have more than one metastasis.